|
 Reglan :
The now FDA black-box warning Reglan (metoclopramide) medication for gastrointestinal disorder treatment has been linked to a serious movement disorder called tardive dyskinesia. On January 26, 2009 the Food and Drug Administration issued an alert which warned consumers against chronic use of the drug leading to the disease that can effect and cause random movements in the tongue, lips or jaw, as well as the face, arms, legs, fingers, toes and even torso.
According to the FDA, development of this condition is directly related to the length of time a patient is taking metoclopramide and the number of doses taken. Those at greatest risk include the elderly, especially older women, and people who have been on the drug for a long time.
Metoclopramide is available in a variety of formulations including tablets, syrups and injections. Names of metoclopramide-containing products include Reglan Tablets, Reglan Oral Disintegrating Tablets, Metoclopramide Oral Solution, and Reglan Injection. More than two million Americans use these products.
Recently published analyses suggest that metoclopramide is the most common cause of drug-induced movement disorders. Another analysis of study data by the FDA showed that about 20 percent of patients in that study who used metoclopramide took it for longer than three months. The FDA has also become aware of continued spontaneous reports of tardive dyskinesia in patients who used metoclopramide, the majority of whom had taken the drug for more than three months.
|
|
Automobile Accidents
